AptaBio Therapeutics Inc
AptaBio Therapeutics Inc., a biopharmaceutical company, develops platform based drugs for intractable diseases. Its platforms include Oxidative stress modulation platform for developing therapeutic agents for diabetes complications, vascular diseases, neurodegenerative diseases, and intractable cancers by controlling oxidative stress; Cancer-associated fibroblast control platform for developing n… Read more
AptaBio Therapeutics Inc (293780) - Total Liabilities
Latest total liabilities as of September 2025: ₩22.51 Billion KRW
Based on the latest financial reports, AptaBio Therapeutics Inc (293780) has total liabilities worth ₩22.51 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
AptaBio Therapeutics Inc - Total Liabilities Trend (2017–2024)
This chart illustrates how AptaBio Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
AptaBio Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of AptaBio Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SCGJWD LOGISTICS PCL NON-VOTING DR
BK:SJWD
|
Thailand | ฿20.07 Billion |
|
AXIOS Sustainable Growth
NYSE:AXAC
|
USA | $1.18 Million |
|
Complete Logistic Services Bhd
KLSE:5136
|
Malaysia | RM67.56 Million |
|
Kuen Chaang Uppertech
TWO:6265
|
Taiwan | NT$100.82 Million |
|
Birla Carbon (Thailand) Public Company Limited
BK:BCT
|
Thailand | ฿4.29 Billion |
|
Unifique Telecomunicações S.A.
SA:FIQE3
|
Brazil | R$1.09 Billion |
|
Korvest Ltd
AU:KOV
|
Australia | AU$30.87 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down AptaBio Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.50 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how AptaBio Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for AptaBio Therapeutics Inc (2017–2024)
The table below shows the annual total liabilities of AptaBio Therapeutics Inc from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩23.24 Billion | -25.42% |
| 2023-12-31 | ₩31.16 Billion | +732.10% |
| 2022-12-31 | ₩3.74 Billion | +15.36% |
| 2021-12-31 | ₩3.25 Billion | -4.64% |
| 2020-12-31 | ₩3.40 Billion | +51.33% |
| 2019-12-31 | ₩2.25 Billion | +11.52% |
| 2018-12-31 | ₩2.02 Billion | -95.26% |
| 2017-12-31 | ₩42.54 Billion | -- |